Hikma Pharmaceuticals invited IFC to provide and arrange financing to support the general corporate purposes of the Company and members of its Group in the MENA region and/or in other World Bank Group countries of operation. Demonstration Effect: Hikma will bring in high quality manufacturing in emerging markets.
Hikma Pharmaceuticals PLC (“Hikma” or the “Company”) and its subsidiaries (the “Group”), is a generic pharmaceutical company incorporated in United Kingdom(“UK”)and listed on the London Stock Exchange (“LSE”). While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (“MENA”) region, the United States (“US”) and Europe. The Company has 29 manufacturing facilities in 11 countries out of which facilities in 5 countries have received US Food and Drug Administration (“FDA”) approval. Hikma’s main business lines include branded, injectables and generic pharmaceuticals. Hikma is a long-standing IFC client since 1987.
|Private Actor 1||Private Actor 1 Role||Private Actor 1 Sector||Relation||Private Actor 2||Private Actor 2 Role||Private Actor 2 Sector|
|-||-||-||-||Hikma Pharmaceuticals PLC||Client||-|
Hikma Pharmaceuticals PLC
+962 6 5802900
P.O. Box: 182400, Amman 11118, Jordan
ACCOUNTABILITY MECHANISM OF IFC
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/